Wyeth Europa

MAIDENHEAD, England - - Data Presented at the 18th EADV Congress add to the Comprehensive Long-Term Data set as Enbrel Reaches Five-Year Anniversary in Treating Patients With Plaque Psoriasis in Europe Data signalling that Enbrel(R) (etanercept) can improve the quality of life for people with psoriasis and psoriatic arthritis were presented at the 18th Congress of the European Academy of Dermatology and Venereology (EADV), as Enbrel(R) (etanercept) reached its five-year anniversary since its approval in Europe as a treatment for psoriasis.

MAIDENHEAD, England - Wyeth Europa, a division of Wyeth (NYSE:WYE), announced today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recommending the approval of the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment of relapsed and/or refractory mantle cell lymphoma (MCL).

MAIDENHEAD, England - My Day for RA Launches Across Europe Today: A Novel 'Goal-Centred' Patient Programme Recognising that rheumatoid arthritis (RA) can cause deformity, disability and loss of independence without effective management - My Day for RA, a new educational programme, launches today to encourage people with RA to understand the impact that their condition can have on their lives now and in the future.